Angiotensin II SPIE-IA kit

PRODUCT EXPLANATION: ACETYLCHOLINESTERASE MARKER IN ENZYME-IMMUNOASSAYS|Grassi J., Pradelles P. Compounds labelled by the acetylcholinesterase of Electrophorus Electricus. Its preparation process and its use as a tracer or marquer in enzymo-immunological determinations. United States patent, N° 1,047,330. September 10, 1991|Grassi J., Pradelles P. The use of Acetylcholinesterase as a Universal marker in Enzyme-Immunoassays. Proceedings of the Third International Meeting on Cholinesterases, American Chemical Society (1991)|Pradelles P., Grassi J., Maclouf J. Enzyme Immunoassays of Eicosanoids Using Acetylcholinesterase. Methods in Enzymology (1990), vol. 187, 24-34|PRODUCT EXPLANATION: ANGIOTENSIN II|Paulis L, Unger T. Novel therapeutic targets for hypertension Nat Rev Cardiol. 2010 Aug;7(8):431-41|PRODUCT EXPLANATION: KIT DEVELOPMENT|Volland H, Pradelles P, Ronco P, Azizi M, Simon D, Créminon C, Grassi J. A solid-phase immobilized epitope immunoassay (SPIE-IA) permitting very sensitive and specific measurement of angiotensin II in plasma. J Immunol Methods. 1999 Aug 31;228(1-2):37-47|Pradelles Ph. Immunometric determination of an antigen or hapten. United states patent, N°5,476,770. December 19; 1995|Kohara K, Tabuchi Y, Senanayake P, Brosnihan KB, Ferrario CM. Reassessment of plasma angiotensins measurement: effects of protease inhibitors and sample handling procedures. Peptides. 1991 Sep-Oct;12(5):1135-41|Grassi J, Créminon C, Frobert Y, Etienne E, Ezan E, Volland H, Pradelles P. Two different approaches for developing immunometric assays of haptens. Clin Chem. 1996 Sep;42(9):1532-6|Valentin MA, Ma S, Zhao A, Legay F, Avrameas A. Validation of immunoassay for protein biomarkers: Bioanalytical study plan implementation to support pre-clinical and clinical studies. J Pharm Biomed Anal. (2011) 55(5): 869-877|European Medicines Agency. Guideline on bioanalytical method validation, 21 July 2011|PRODUCT CITATIONS|Efrati S, Berman S, Hamad RA, Siman-Tov Y, Ilgiyaev E, Maslyakov I, Weissgarten J. Effect of captopril treatment on recuperation from ischemia/reperfusion-induced acute renal injury. Nephrol Dial Transplant. 2012 Jan;27(1):136-45|Amit Dagan, Jyothsna Gattineni, Sabeen Habib and Michel Baum. Effect of Prenatal Dexamethasone on Postnatal Serum and Urinary Angiotensin II Levels. Am J Hypertens 2010; 23:420-424|Ying-Hong Feng, Lingyin Zhou, Rongde Qiu and Robin Zeng. Single Mutations at Asn295 and Leu305 in the Cytoplasmic Half of Transmembrane α-Helix Domain 7 of the AT1 Receptor Induce Promiscuous Agonist Specificity for Angiotensin II Fragments: A Pseudo-Constitutive Activity. Molecular Pharmacology August 2005, 68 (2) 347-355|Stevens VA, Saad S, Poronnik P, Fenton-Lee CA, Polhill TS, Pollock CA. The role of SGK-1 in angiotensin II-mediated sodium reabsorption in human proximal tubular cells. Nephrol Dial Transplant. 2008 Jun;23(6):1834-43|Yanes LL, Romero DG, Iles JW, Iliescu R, Gomez-Sanchez C, Reckelhoff JF. Sexual dimorphism in the renin-angiotensin system in aging spontaneously hypertensive rats. Am J Physiol Regul Integr Comp Physiol. 2006 Aug;291(2):R383-90|Yvan-Charvet L, Massiéra F, Lamandé N, Ailhaud G, Teboul M, Moustaid-Moussa N, Gasc JM, Quignard-Boulangé A. Deficiency of angiotensin type 2 receptor rescues obesity but not hypertension induced by overexpression of angiotensinogen in adipose tissue. Endocrinology. 2009 Mar;150(3):1421-8|Van Ginkel a,b, De Haan, et al. Exercise intensity modulates capillary perfusion in correspondence with ACE I/D modulated serum angiotensin II levels. Applied & Translational Genomics 4 (2015) 33–37|Kawaguchi, Takagi et al. Angiotensin II in the Lesional Skin of Systemic Sclerosis Patients Contributes to Tissue Fibrosis Via Angiotensin II Type 1 Receptors. ARTHRITIS & RHEUMATISM, Vol. 50, No. 1, January 2004, pp 216–226|Miceli, Burt et al. Stretch reduces nephrin expression via an angiotensin II-AT1-dependent mechanism in human podocytes: effect of rosiglitazone. Am J Physiol Renal Physiol 298: F381–F390, 2010